Thelansis

 Acanthamoeba keratitis (AK), a rare and challenging cornea infection to diagnose and treat effectively, is caused by various genotypes of the Acanthamoeba organism, classified as T1–T22 based on 18s rRNA gene typing. Clinical presentation and treatment response vary depending on the genotype. Transmission occurs through corneal contact with contaminated substances, with human cases often linked to tainted water, soil, or eye trauma. The disease progresses through two phases: an initial phase affecting only the corneal epithelium, followed by invasion into the underlying stroma, resulting in significant damage to the collagen matrix and triggering intense inflammation. AKANTIOR® (polihexanide), a novel anti-amoebic polymer, holds promise as the first approved drug for treating Acanthamoeba keratitis worldwide. Polihexanide targets both trophozoites and cysts of the Acanthamoeba protozoan. ·        The estimated incidence of Acanthamoeba keratitis (AK...

 Acanthamoeba keratitis (AK) is a rare cornea infection that is difficult to diagnose and treat properly. It can be a sight-threatening disease. Acanthamoeba is currently divided into twenty-two different genotypes (T1–T22) based on 18s rRNA gene typing. Based on genotype variations, clinical presentation and response to therapy vary. The pathogen is transmitted through corneal contact with a contaminated substance. Most cases seen in humans seem to be associated with contaminated water, soil, or trauma to the eye. The progression of Acanthamoeba keratitis occurs in two main phases. An initial phase where infiltration is limited to the corneal epithelium, and a second phase where the parasite invades the underlying stroma. Once in the stroma, extensive damage to the collagen matrix occurs, which provokes intense inflammation. ·        The estimated incidence of Acanthamoeba keratitis (AK) cases with soft contact lens wearers ranges between 4.5 to 7.8...